305 Bridge to Transplant Using BiVAD or Total Artificial Heart: Is There a Survival Difference?

2012 ◽  
Vol 31 (4) ◽  
pp. S109-S110
Author(s):  
A. Nguyen ◽  
M. Pozzi ◽  
C. Mastroianni ◽  
P. Leprince ◽  
P. Alain ◽  
...  
2021 ◽  
Vol 40 (4) ◽  
pp. S528
Author(s):  
G.T. Gibson ◽  
S. Rangasamy ◽  
J. Contreras ◽  
A. Singhvi ◽  
A. Fox ◽  
...  

1991 ◽  
Vol 2 (3) ◽  
pp. 587-597
Author(s):  
Lawrence E. Barker

In the early 1800s, an awareness of potential ventricular failure stimulated interest in artificial heart replacement. In 1937 the first total artificial heart (TAH) was implanted into the chest of a dog by Russian physicians. The primary driving force for mechanical cardiac assistance developed from the necessity for circulatory assistance in order to perform corrective cardiac surgery. In 1953 the first successful closure of an atrial septal defect using extracorporeal circulation was performed. During the following decade the concept of using mechanical devices to assist the failing heart was aggressively pursued. This culminated in the first implant of a TAH in a human in 1969 as a bridge to transplant. Clinical implant of the TAH as a permanent device was performed in 1982 by researchers at the University of Utah. This patient lived for 112 days. Three successive permanent implants were performed in Louisville, Kentucky, with one patient surviving for 620 days. All of these permanent TAH patients suffered from device-related complications including bleeding, infection, and thromboembolic events. It became apparent that the present configuration of the TAH with its external drive lines and large air console was not ideal for long-term support. In 1985 the first implant of the Symbion J-7-100 TAH (Jarvik-7) as a bridge to transplant was performed. This patient was supported by the device for 9 days and was successfully transplanted and discharged home. Since 1985 more than 170 patients have been bridged using the Symbion J-7 TAH with more than 70% of these patients being successfully transplanted. The incidence of thromboembolic events has dramatically reduced with better understanding of anticoagulation requirements. Infection continues to be the greatest potential complication with these patients. In spite of this, the pneumatic TAH has proved to be an adequate bridge to transplant device


1998 ◽  
pp. 421-423
Author(s):  
Ricardo J. Moreno-Cabral ◽  
Robert M. Adamson ◽  
Walter P. Dembitsky ◽  
Pat O. Daily ◽  
Francisco A. Arabía ◽  
...  

2021 ◽  
Vol 8 (9) ◽  
pp. 126
Author(s):  
Brendan Le Picault ◽  
Charles-Henri David ◽  
Pierre-Louis Alexandre ◽  
Cédric Lenoble ◽  
Philippe Bizouarn ◽  
...  

Introduction: Circulatory assistance from a SynCardia Total Artificial Heart (SynCardia-TAH) is a reliable bridge-to-transplant solution for patients with end-stage biventricular heart failure. Ischemic strokes affect about 10% of patients with a SynCardia-TAH. We report for the first time in the literature two successful thrombectomies to treat the acute phase of ischemic stroke in two patients treated with a SynCardia-TAH in the bridge-to-transplant (BTT). Case report: We follow two patients with circulatory support from a SynCardia-TAH in the bridge-to-transplant for terminal biventricular cardiac failure with ischemic stroke during the support period. An early in-hospital diagnosis enables the completion of a mechanical thrombectomy within the first 6 h of the onset of symptoms. There was no intracranial hemorrhagic complication during or after the procedure and the patients fully recovered from neurological deficits, allowing a successful heart transplant. Conclusion: This case report describes the possibility of treating ischemic strokes under a SynCardia-TAH by mechanical thrombectomy following the same recommendations as for the general population with excellent results and without any hemorrhagic complication during or after the procedure.


2016 ◽  
Vol 19 (1) ◽  
pp. 014
Author(s):  
Amit Prasad ◽  
Kai Singbartl ◽  
Jacqueline Boone ◽  
Behzad Soleimani ◽  
Mohamad Zeriouh ◽  
...  

As a bridge to transplant, the Syncardia™ total artificial heart (TAH) is an option for patients who are not candidates for left ventricular assist devices (LVAD) due to right ventricular failure. The need for nutritional support in these patients is essential for a favorable outcome. Low body mass indexes and albumin levels have been associated with increased morbidity and mortality in cardiac surgery patients [Alverdy 2003]. It is not uncommon for postoperative patients to have difficulty in consuming enough calories after surgery, which is further complicated by a hypermetabolic demand due to surgical stress. Enteral nutrition has typically been favored for gut mucosal integrity and bacterial flora [Alverdy 2003] [Engleman 1999]. We describe the need for prolonged enteral nutritional support in a TAH patient that was accomplished with a percutaneous endoscopic gastrostomy (PEG) tube.


ASAIO Journal ◽  
2020 ◽  
Vol 66 (2) ◽  
pp. e33-e35
Author(s):  
Gary S. Beasley ◽  
Kiona Allen ◽  
Elfride Pahl ◽  
Lindsay Jackson ◽  
Osama Eltayeb ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document